Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

POLARIS Progress in Leukodystrophies: Advance, Rate and Implement new treatment Strategies

Coordinator
Stichting Amsterdam Umc, Netherlands
Runs
1 October 2026 to 30 September 2030
Status
Running
EU funding
€4.6m
Total cost
—
Partners
32 organisations in 12 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101311855

What the project is doing

In the project's own words, from its summary on CORDIS.

Leukodystrophies are severe genetic disorders of the brain white matter that cause profound disability and premature death, mostly in children, and lack effective treatments. POLARIS aims to accelerate therapy development by training the next generation of leukodystrophy scientists capable of collaborating across the full spectrum of discovery, development, evaluation and implementation of innovative and accessible therapies.

Researchers will develop gene-therapy approaches (RO1), pharmacological strategies (RO2) and treatment-evaluation tools (RO3) to advance therapies for leukodystrophies and strengthen R&I frameworks for other rare diseases. A key barrier to progress is fragmentation: discovery, preclinical development, outcome definition and regulatory pathways rarely coexist in a single environment. POLARIS bridges this through 3 cross-cutting themes: (I) Affordable, Accessible and Timely—embedding cost, accessibility and real-world feasibility from the earliest stages; (II) Relevant Outcomes—focusing on what matters to patients, caregivers, clinicians, regulators and society; and (III) Transferable Knowledge & Tools—producing broadly applicable insights and platforms beyond individual diseases.

The programme integrates all relevant stakeholders, including strong engagement of patient organisations, industry and public bodies. POLARIS generates major scientific advances through innovative gene-therapy and pharmacological platforms, validated biomarkers and harmonised outcome measures that directly support future clinical trials. Its end-to-end translational pipeline creates scalable technologies relevant to a wide range of rare neurological disorders.

POLARIS enhances researchers’ career prospects, skills, employability and contributions to Europe’s innovation capacity. By reducing development barriers and enabling more effective, affordable treatments, POLARIS delivers substantial economic and societal benefits for patients, families and healthcare systems.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Amsterdam UmcAmsterdamNetherlandsCoordinator
Vrije Universiteit BrusselBruxelles / BrusselBelgiumParticipant
Universitat ZurichZurichSwitzerlandParticipant
Kypriako Idryma Erevnon Gia Ti Myiki DistrofiaAgios DometiosCyprusParticipant
Data Powered Therapeutics GmbHGöttingenGermanyAssociatedpartner
Eberhard Karls Universitaet TuebingenTuebingenGermanyParticipant
Enamine Germany GmbHFrankfurt am MainGermanyAssociatedpartner
Fundacio Institut Hospital Del Mar D Investigacions MediquesBarcelonaSpainParticipant
Universidad Pompeu FabraBarcelonaSpainAssociatedpartner
Universitat De BarcelonaBarcelonaSpainAssociatedpartner
Oulun YliopistoOuluFinlandAssociatedpartner
Institut Du Cerveau Et De La Moelle EpiniereParisFranceParticipant
Sorbonne UniversiteParisFranceAssociatedpartner
Consiglio Nazionale Delle RicercheRomaItalyAssociatedpartner
Istituto Superiore Di SanitaRomaItalyParticipant
Universita Degli Studi Di Roma La SapienzaRomaItalyAssociatedpartner
ELA InternationalLuxembourgLuxembourgAssociatedpartner
Agentschap College Ter Beoordeling Van GeneesmiddelenUtrechtNetherlandsParticipant
Fundament SubsidieadviesHilversumNetherlandsAssociatedpartner
Stichting VuAmsterdamNetherlandsParticipant
Synaptologics BVLeidenNetherlandsParticipant
Universiteit Van AmsterdamAmsterdamNetherlandsAssociatedpartner
Vereniging Innovatieve GeneesmiddelenDen HaagNetherlandsAssociatedpartner
Alex, The Leukodystrophy CharityLondonUnited KingdomAssociatedpartner
Orchard Therapeutics (Europe) LimitedLondonUnited KingdomAssociatedpartner
The Anna Freud CentreLondonUnited KingdomAssociatedpartner
The University of LiverpoolLiverpoolUnited KingdomAssociatedpartner
University College LondonLondonUnited KingdomParticipant
University of Newcastle Upon TyneNewcastle Upon TyneUnited KingdomAssociatedpartner
University of YorkYork North YorkshireUnited KingdomParticipant
Zantiks LimitedRoystonUnited KingdomAssociatedpartner
Alliance MLC FoundationMiddletown, DEUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI